Pharmaceutical company Chrysalis BioTherapeutics Inc reported on Wednesday the receipt of the Orphan Drug Designation (ODD) for its lead compound TP508 (rusalatide acetate) for the treatment of acute radiation syndrome (ARS), from the US Food and Drug Administration (FDA) Office of Orphan Product Development and the European Medicines Agency (EMA).
Following exposure to high levels of nuclear radiation, individuals develop ARS or radiation sickness affecting multiple organ systems and often leading to death within days, weeks, or months of exposure.
TP508 is a regenerative peptide drug representing a natural part of human thrombin that is released upon tissue injury to initiate healing.
The compound has demonstrated safety and potential efficacy in non-clinical and in human clinical tissue repair trials, Chrysalis BioTherapeutics said.
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval
United Therapeutics reports positive phase 1 data for bioengineered liver in acute liver failure